As the immune system’s first responders, natural killer (NK) cells are essential for the rapid detection and elimination of cancer. Their ability to kill cancer cells without prior sensitization makes them an ideal immunotherapy candidate. NK cells induce an anti-tumor immune response known as antibody-dependent cellular cytotoxicity (ADCC) when activating receptors, such as CD16, bind to monoclonal antibodies (mAbs) on target cells. Combining adoptive NK cell infusions with mAbs is a promising strategy for treating cancer.
Continue to Application Note
Please fill form below to continue to Application Note.
